8-K: Treace Medical Q3 Revenue Up 11%, Cuts Full-Year Outlook

Treace Medical Concepts reported 11% revenue growth in Q3 2025 but revised its full-year guidance downward due to market headwinds and a shift in surgeon preferences.

Summary

• Q3 2025 revenue reached $50.2 million, an 11% increase compared to $45.1 million in Q3 2024.
• The company reported a net loss of $(16.3) million, or $(0.26) per share, for Q3 2025, compared to $(15.4) million, or $(0.25) per share, in Q3 2024.
• Adjusted EBITDA loss improved by 49% to $(2.6) million in Q3 2025, from $(5.1) million in Q3 2024.
• Full-year 2025 revenue guidance was revised downward to $211 million to $213 million (1% to 2% growth), from previous guidance of $224 million to $230 million.
• Full-year 2025 Adjusted EBITDA guidance was revised to a loss of $6.5 million to $7.5 million, compared to previous guidance of breakeven.
• The company expanded its bunion technology portfolio with the full market release of the Nanoplasty and Percuplasty 3D MIS Osteotomy Systems, and the SpeedMTP MTP Fusion System.
• The global patent portfolio now includes 122 granted patents and 194 pending patent applications.
• Richard W. Mott retired from the Board of Directors, Compensation Committee, Nominating and Corporate Governance Committee, and as Lead Independent Director on November 3, 2025, for personal reasons.
• The Board reduced its size from eight to seven members on November 5, 2025, resulting in no current vacancies.

Sentiment

Score: 4

Explanation: While Q3 revenue growth was positive and Adjusted EBITDA improved, the significant downward revision of full-year guidance for both revenue and profitability, coupled with increasing net loss and declining gross margin, indicates substantial headwinds and a challenging outlook. The retirement of a key independent director also adds a minor negative.

Positives

• Q3 2025 revenue grew 11% to $50.2 million, demonstrating market penetration with an expanded portfolio.
• Adjusted EBITDA improved significantly by 49% to a loss of $(2.6) million in Q3 2025 compared to the prior year.
• Expanded bunion technology portfolio with the full market release of Nanoplasty, Percuplasty 3D MIS Osteotomy Systems, and SpeedMTP MTP Fusion System.
• Broadened global patent portfolio now totals 122 granted patents and 194 pending applications.
• Presented positive clinical data from Align3D Lapiplasty and MTA3D Adductoplasty clinical studies.
• Cash usage decreased by 17% in Q3 2025 and 58% for the nine months ended September 30, 2025, compared to the prior year.

Negatives

• Full-year 2025 revenue guidance was significantly reduced to $211 million-$213 million (1%-2% growth) from $224 million-$230 million.
• Full-year 2025 Adjusted EBITDA guidance was revised from breakeven to a loss of $6.5 million-$7.5 million.
• Net loss increased to $(16.3) million in Q3 2025 from $(15.4) million in Q3 2024.
• Gross margin decreased to 79.1% in Q3 2025 from 80.1% in Q3 2024.
• Lapiplasty volumes have been impacted by a shift in surgeon and patient preferences towards minimally invasive solutions.
• Broader macroeconomic conditions and softer consumer sentiment are resulting in a greater number of deferrals of elective bunion procedures.
• Higher than planned sales to a limited number of stocking distributors in Q3 are not expected to recur at the same level.

Risks

• Increased competition in the bunion treatment market.
• Evolving surgeon and patient preferences for minimally invasive bunion solutions impacting demand for existing products.
• Broader macroeconomic conditions and softer consumer sentiment leading to lower patient demand for elective bunion surgery.
• Challenges in effectively responding to and mitigating the impact of current market environment changes.
• Ability to protect and enforce intellectual property rights, including through ongoing patent infringement and unfair competition suits.
• Success in defending against securities class actions and intellectual property infringement by third parties.
• Potential impact of changes in tariff and trade policies or protracted government shutdowns.
• Variability in the amount and timing of orders from stocking distributors and other customers.

Future Outlook

The company revised its full-year 2025 revenue guidance downward to $211 million to $213 million, representing 1% to 2% growth, from its previous range of $224 million to $230 million. The Adjusted EBITDA outlook for full-year 2025 was also revised to a loss of $6.5 million to $7.5 million, compared to prior breakeven expectations. This revision is primarily due to anticipated lower sales from the Lapiplasty System, driven by evolving surgeon preferences for minimally invasive osteotomy procedures, increased competition, and reduced patient demand for elective bunion surgery stemming from macroeconomic conditions and softer consumer sentiment. Despite these challenges, the company aims to leverage its new products, innovation pipeline, and commercial organization to drive market share gains and improve profitability.

Management Comments

• "Our revenue growth in the third quarter reflects greater market penetration with our expanded portfolio of solutions, along with higher than planned sales to a limited number of stocking distributors that we do not expect to recur at the same level."
• "At the same time, Lapiplasty volumes have been impacted as surgeons and patient preferences shift towards minimally invasive solutions, and we are seeing broader macroeconomic conditions and softer consumer sentiment resulting in a greater number of deferrals of elective bunion procedures."
• "These headwinds have continued early into the fourth quarter, and as a result, we are revising our outlook for the full year."
• "Looking ahead, while we have lowered our growth expectations for 2025, we remain the leader in the bunion market, and we believe we are in a stronger position to drive market share gains with our new products, innovation pipeline and ability to leverage investments in our commercial organization."
• "Our team is focused on increasing our topline growth, improving profitability and delivering value to our shareholders."

Industry Context

The medical technology sector for orthopedic procedures, particularly elective bunion surgeries, is experiencing a notable shift towards minimally invasive solutions. This trend, combined with broader macroeconomic uncertainties and cautious consumer sentiment, is influencing patient demand and surgeon preferences. Companies like Treace Medical Concepts, which have a strong presence with established procedures such as Lapiplasty, are adapting by expanding their product portfolios to include new minimally invasive options to maintain market leadership and address evolving clinical needs. The competitive landscape in this specialized area is also intensifying, requiring continuous innovation and strategic commercial investments.

Management Changes

Corporate Governance

Legal Proceedings

• Litigation costs related to patent infringement lawsuits amounted to $1.038 million in Q3 2025 and $2.548 million for the nine months ended September 30, 2025.
• The company is actively protecting and enforcing its intellectual property rights, including through recently filed patent infringement and unfair competition suits.
• The company is also engaged in defending against securities class actions and intellectual property infringement by third parties.

Stakeholder Impact

• Shareholders: Negative impact due to significant downward revision of full-year revenue and profitability guidance, likely leading to stock price pressure.
• Customers (Surgeons/Patients): Positive impact from the expansion of the product portfolio, including new minimally invasive options, addressing evolving preferences.
• Employees: Potential impact from restructuring costs mentioned in Q3 2025, which relate to severance payments and other post-employment benefits.
• Creditors: Liquidity remains at $80.6 million, but increased net loss and revised EBITDA loss may raise concerns about future profitability and debt servicing capacity, despite decreasing cash usage.

Next Steps

• Host a conference call on November 6, 2025, at 4:30 p.m. ET to discuss Q3 2025 financial results.
• Continue to drive market share gains with new products and innovation pipeline.
• Focus on increasing topline growth and improving profitability.

Key Dates

Recommendation

The significant downward revision of full-year revenue and Adjusted EBITDA guidance, coupled with increasing net loss and declining gross margin, indicates a deteriorating financial outlook and substantial operational headwinds. The company faces challenges from evolving surgeon preferences, increased competition, and macroeconomic conditions impacting elective procedures. While new products are being launched, their impact is not yet sufficient to offset these pressures, leading to a substantially weaker financial forecast. This suggests a negative outlook for the stock.

Keywords

Medical Technology, Bunion Surgery, Orthopaedics, Lapiplasty, Minimally Invasive Surgery, Foot and Ankle, Financial Results, Guidance Revision, TMCI, Medical Devices, Corporate Governance